{"entity":{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","aka":[],"tldr":"An Australian nuclear medicine pioneer who built Peter MacCallum Cancer Centre's molecular imaging and therapy service into a world-renowned unit over three decades, and now runs an independent theranostics centre in Melbourne.","summary":"Rodney Hicks directed cancer imaging and later the Centre for Molecular Imaging and Therapeutic Nuclear Medicine at Melbourne's Peter MacCallum Cancer Centre for around three decades, building a nuclear medicine service that helped pioneer clinical PET/CT in Australia and later 177Lu-PSMA-617 radioligand therapy. He was a senior author on the single-centre LuPSMA phase 2 trial and contributed to the proPSMA randomised trial of PSMA PET-CT for staging high-risk prostate cancer, and to methods for single-time-point SPECT/CT dosimetry of 177Lu-PSMA-617 therapy.\n\nAfter leaving Peter Mac in 2021, he founded the Melbourne Theranostic Innovation Centre (MTIC), where he is Executive Chairman and Chief Medical Officer, delivering theranostics clinical and research services in partnership with industry, while retaining a professorial appointment at the University of Melbourne.","asOf":"2026-09-22","links":[{"label":"Melbourne Theranostic Innovation Centre","url":"https://www.mtic.net.au/mtic-team/professor-rodney-hicks"},{"label":"proPSMA trial, The Lancet 2020","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30314-7/fulltext"}],"tags":["PSMA","theranostics","clinician"],"related":["propsma","paper-propsma-hofman-lancet-2020","pluvicto","peter-mac","amir-iravani","lu-177"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Executive Chairman and Chief Medical Officer, Melbourne Theranostic Innovation Centre; Professor of Medicine, University of Melbourne (previously Director, Centre for Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, until 2021)","specialisms":["theranostics programme building","neuroendocrine tumour PET","PSMA radioligand therapy dosimetry"],"profiles":[{"label":"Melbourne Theranostic Innovation Centre team page","url":"https://www.mtic.net.au/mtic-team/professor-rodney-hicks"},{"label":"Discovery Medicine biography","url":"https://www.discoverymedicine.com/Rodney-J-Hicks/about/"}],"papers":[{"title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30198-0"},{"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","journal":"The Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30314-7"},{"title":"Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors","journal":"Journal of Nuclear Medicine","year":2020,"doi":"10.2967/jnumed.119.233411"}]},"route":"/people/rodney-hicks/","neighbours":{"trial":[{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/"}],"paper":[{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/"}],"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"institution":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"person":[{"id":"amir-iravani","kind":"person","name":"Amir Iravani","route":"/people/amir-iravani/"}],"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}]}}